Nifedipine facilitates neurotransmitter release independently of calcium channels

Proc Natl Acad Sci U S A. 2003 May 13;100(10):6139-44. doi: 10.1073/pnas.0936131100. Epub 2003 Apr 24.

Abstract

Nifedipine, a drug used for treatment of hypertension and angina, exerts its effect by calcium channel blockade and nitric oxide production. We report here a previously uncharacterized action of nifedipine on central synaptic transmission that may partially explain its side effects. Nifedipine causes a long-lasting facilitation of tetrodotoxin-insensitive spontaneous glutamate release. This effect is independent of its L-type calcium channel blocking effect, and is not mimicked by other dihydropyridines such as nimodipine, nicardipine, or Bay K 8644. The effect was dose dependent, with EC(50) of 7.8 microM, with the lowest effective dose being 100 nM, a clinically relevant dose. At 10 microM, the increase is 14.7-fold. This effect is largely calcium-independent, because Cd(2+), thapsigargin, or BAPTA-AM [1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid-acetoxymethyl ester] did not inhibit the nifedipine effect. Thus, nifedipine seems to act on the release process downstream of calcium entry or release. Protein kinases A or C do not mediate its effect, because it is not blocked by inhibitors of these kinases. Our finding indicates that nifedipine may be a useful tool as a secretagogue to directly target the release process, but raises caution for its use as an L-type calcium channel blocker.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / pharmacology
  • Animals
  • Brain / drug effects
  • Brain / physiology*
  • Cadmium / pharmacology
  • Calcium Channel Blockers / pharmacology
  • Calcium Channels, L-Type / drug effects
  • Calcium Channels, L-Type / physiology*
  • Egtazic Acid / analogs & derivatives*
  • Egtazic Acid / pharmacology
  • In Vitro Techniques
  • Kinetics
  • Male
  • Neurotransmitter Agents / metabolism*
  • Nifedipine / pharmacology*
  • Quinoxalines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Thapsigargin / pharmacology

Substances

  • Calcium Channel Blockers
  • Calcium Channels, L-Type
  • Neurotransmitter Agents
  • Quinoxalines
  • Cadmium
  • 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester
  • Egtazic Acid
  • FG 9041
  • Thapsigargin
  • 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester
  • Nifedipine